Evidence map›Paper›PMID 42080701›Full record

Trial reportJNCI cancer spectrum2026

Financial reimbursement for clinical trial participation costs: a pilot feasibility study.

Courtney P Williams, Nicole L Henderson, Nusrat Jahan, Erica Stringer-Reasor, Andres Azuero, Maria Pisu, Rebecca C Arend, Gabrielle B Rocque

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05871125 (Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05871125 nacompletednot on this map

Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2023 to 2025Enrolled39ConditionsBreast CancerArmsReimbursement
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Courtney P WilliamsDivision of General Internal Medicine & Population Science, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0001-5328-7517
Nicole L HendersonO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0003-2101-3065
Nusrat JahanDivision of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0002-9311-0780
Erica Stringer-ReasorDivision of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.
Andres AzueroSchool of Nursing, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0001-9883-1424
Maria PisuDivision of General Internal Medicine & Population Science, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0001-9329-3268
Rebecca C ArendO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States.
Gabrielle B RocqueO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0003-4188-9785

Funding

Breast Cancer Research Foundation of AlabamaCommunity Foundation of Greater Birmingham Women's Breast Health FundUAB O'Neal Comprehensive Cancer Center O'Neal Invests P30CA013148
6 · The paper itself

Abstract

backgroundClinical trial participants rarely represent the real-world treatment population, potentially due to costs associated with participation. Monetary reimbursement for trial-related costs could address financial barriers to trial recruitment and retention.

methodsThis mixed-methods, pilot, feasibility study provided financial reimbursement to women with breast cancer participating in a clinical trial. Patients were reimbursed $1000/month during their first 4 months of trial participation, surveyed biweekly to assess changes in financial toxicity, and then interviewed to explore the effects of receiving reimbursement on trial-related costs and recruitment and retention. Mixed-effect modeling and thematic analysis were completed. Feasibility was defined as 80% retention of patients on the reimbursement study, with those retained completing 75% of surveys.

resultsOf 39 consented patients, 33 patients completed the pilot study (85% retention, 100% survey completion). Patients were a median 52 years old (interquartile range = 44-59), 48% Black, 67% privately insured, and 42% found it difficult to live on their current income. Patient financial toxicity modestly decreased. Patients (n = 32) reported using the reimbursement to pay for trial visit-related food, transportation, caregiver expenses, and out-of-pocket medical costs. Patients felt receiving reimbursement affected trial retention more so than recruitment, stating "I would have enrolled regardless … [but knowing] it wasn't going to place a financial strain on us because of these reimbursements. … It made it easier for me to feel good about continuing."

conclusionReimbursement for clinical trial-related costs is feasible, suggests decreases in financial toxicity, and is a promising approach to improve trial retention outcomes in women with breast cancer. CLINICALTRIALS.GOV ID: NCT05871125.

Indexed as

Breast NeoplasmsClinical Trials as TopicPatient SelectionAdultFeasibility StudiesFemaleHumansMiddle AgedPilot Projects

Identifiers

PMID42080701
PMCPMC13228128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.